Cargando…

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review

BACKGROUND: Aducanumab, a new monoclonal antibody that targets β-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimer's disease (AD). The approval of this drug without a confirmed significant clinical impact has resulted in several debates. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beshir, Semira Abdi, Aadithsoorya, A. M., Parveen, Affana, Goh, Sheron Sir Loon, Hussain, Nadia, Menon, Vineetha Bharathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926483/ https://www.ncbi.nlm.nih.gov/pubmed/35308835 http://dx.doi.org/10.1155/2022/9343514

Ejemplares similares

A narrative review of approved and emerging anti-obesity medications
por: Abdi Beshir, Semira, et al.
Publicado: (2023)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Alzheimer disease neuropathology in a patient previously treated with aducanumab
por: Plowey, Edward D., et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer’s Disease
por: Geerts, Hugo, et al.
Publicado: (2021)

Should Canadian patients look forward to aducanumab for Alzheimer disease?
por: Watt, Jennifer A., et al.
Publicado: (2021)

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
por: Lalli, Giovanna, et al.
Publicado: (2021)

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
por: Herring, William L., et al.
Publicado: (2021)

Aducanumab for Alzheimer’s disease: The never‐ending story that nurses should know
por: Petch, Joel, et al.
Publicado: (2021)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease
por: Abyadeh, Morteza, et al.
Publicado: (2021)

Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
por: Sinha, Pranay, et al.
Publicado: (2022)

Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
por: Yigit, Vahit, et al.
Publicado: (2023)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Aducanumab as a Novel Treatment for Alzheimer’s Disease: A Decade of Hope, Controversies, and the Future
por: Esang, Michael, et al.
Publicado: (2021)

Erstes kausal wirkendes Medikament gegen Alzheimer?: Die FDA lässt Aducanumab zu
por: Hager, Klaus
Publicado: (2021)

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

Under-Represented Populations Left Out of Alzheimer’s Disease Treatment with Aducanumab: Commentary on Ethics
por: Padala, Sanjana P., et al.
Publicado: (2022)

What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?
por: Wallin, Anders, et al.
Publicado: (2022)

Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Kumar, Dhiraj, et al.
Publicado: (2021)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Weighing the necessities and concerns of deprescribing among older ambulatory patients and primary care trainees: a qualitative study
por: Goh, Sheron Sir Loon, et al.
Publicado: (2023)

Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review
por: Dickson, Samuel P., et al.
Publicado: (2023)

Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
por: Zissimopoulos, Julie, et al.
Publicado: (2022)

Aducanumab: evidence from clinical trial data and controversies
por: Tampi, Rajesh R, et al.
Publicado: (2021)

Estimated Annual Spending on Aducanumab in the US Medicare Program
por: Mafi, John N., et al.
Publicado: (2022)

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
por: Salloway, Stephen, et al.
Publicado: (2021)

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease
por: Kandadi Muralidharan, Kumar, et al.
Publicado: (2021)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2020)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

A sporadic Alzheimer's blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies
por: Wasielewska, Joanna M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aobimr26f280kpks91pimc3emm